

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Julie Staple, applicant's representative on June 17, 2008.

The application has been amended as follows:

The claims have been amended to read:

1. - 6. (Canceled)

7. (Currently Amended) A method of producing an autophilic antibody by chemical or genetic engineering techniques, wherein the autophilic antibody contains a T15 autophilic peptide having the amino acid sequence shown in SEQ ID NO. 1 attached to the immunoglobulin component of the antibody, and wherein the T15 peptide of the autophilic antibody is crosslinked to a nucleotide affinity site of the immunoglobulin, wherein the antibody binds to an antigen.

8. (Currently Amended) A method of producing an autophilic antibody by chemical or genetic engineering techniques, wherein the autophilic antibody contains a T15 autophilic peptide having the amino acid sequence shown in SEQ ID NO. 1 attached to the immunoglobulin component of the antibody, and wherein the T15

peptide is crosslinked to a carbohydrate site of the Fc portion of the immunoglobulin, wherein the antibody binds to an antigen.

9. (Currently Amended) A method of producing an autophilic antibody by chemical or genetic engineering techniques, wherein the autophilic antibody contains a T15 autophilic peptide having the amino acid sequence shown in SEQ ID NO. 1 attached to the immunoglobulin component of the antibody, and wherein the T15 peptide is conjugated to an amino or sulfhydryl group of the immunoglobulin, wherein the antibody binds to an antigen.

10. (Currently Amended) A method of producing an autophilic antibody by chemical or genetic engineering techniques, wherein the autophilic antibody contains a T15 autophilic peptide having the amino acid sequence shown in SEQ ID NO. 1 attached to the immunoglobulin component of the antibody, and wherein the autophilic antibody is expressed as a fusion protein containing the T15 autophilic sequence, wherein the antibody binds to an antigen.

11.- 17. (Canceled)

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANNE M. GUSSOW whose telephone number is (571)272-6047. The examiner can normally be reached on Monday - Friday 8:30 am - 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Anne M. Gusow

June 17, 2008

/David J Blanchard/
Primary Examiner, Art Unit 1643